Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C4529962
Disease: Fatty Liver Disease
Fatty Liver Disease
0.100 Biomarker disease BEFREE Histological staining's, and commercially available kits for ALT and AST and hepatic contents of TG, TC, MDA, SOD, and GSH were used to assess NASH. 30537674 2019
CUI: C4529962
Disease: Fatty Liver Disease
Fatty Liver Disease
0.100 Biomarker disease BEFREE Histological staining's, and commercially available kits for serum ALT and AST and hepatic contents of TG, TC, MDA, SOD, and GSH were used to assess NASH. 30579258 2019
CUI: C4529962
Disease: Fatty Liver Disease
Fatty Liver Disease
0.100 AlteredExpression disease BEFREE Supplementation of 1,25(OH)<sub>2</sub>D<sub>3</sub> in CDHF-diet mice showed decreased serum levels of ALT, AST, indicating the improvement in overall liver function, and suppressed histological NASH regarding fibrosis stage, lobular inflammation, and steatosis compared to the OVX group. 30825110 2019
CUI: C4529962
Disease: Fatty Liver Disease
Fatty Liver Disease
0.100 Biomarker disease BEFREE In addition, HIF1α silencing significantly decreased HIF1α, biochemical indices (ALT, AST, and TG), inflammatory factors (TNFα, IL6, and IL1β), and angiogenesis indices (CD34 and VEGFR2), consequently, improved the hepatic fibrosis score in the rat model of combined hypoxia and NASH. 30668625 2019
CUI: C4529962
Disease: Fatty Liver Disease
Fatty Liver Disease
0.100 AlteredExpression disease BEFREE Serum ALT, AST, and TG levels were increased in NASH mice. 29735799 2019
CUI: C4529962
Disease: Fatty Liver Disease
Fatty Liver Disease
0.100 Biomarker disease BEFREE The classification performance of validated miRNAs (and their ratios) for NASH was better than that reached by AST, whereas for advanced fibrosis prediction miRNAs did not perform better than the FIB-4 algorithm. 30006517 2018
CUI: C4529962
Disease: Fatty Liver Disease
Fatty Liver Disease
0.100 Biomarker disease BEFREE Those with NASH had significantly higher (p < 0.05) pre-VLCD ALT, AST, insulin resistance, and proportion of individuals with diabetes compared to those with NL. 29098545 2018
CUI: C4529962
Disease: Fatty Liver Disease
Fatty Liver Disease
0.100 AlteredExpression disease BEFREE Meanwhile, BP increased the levels of SOD (superoxide dismutase), GSH (reduced glutathione) and HDL-C (high-density lipoprotein cholesterol), and reduced the levels of AST (aspartate aminotransferase), ALT (alanine aminotransferase), TG (triglycerides), LDL-C (low-density lipoprotein cholesterol) and MDA (malondialdehyde) in NASH models (<i>p</i> < 0.05). 28264426 2017
CUI: C4529962
Disease: Fatty Liver Disease
Fatty Liver Disease
0.100 AlteredExpression disease BEFREE OCA reduced liver weight and lipid in NASH mice (both by -17%) but had no effect on plasma ALT or AST levels. 29107284 2017
CUI: C4529962
Disease: Fatty Liver Disease
Fatty Liver Disease
0.100 GeneticVariation disease BEFREE In multivariate analysis, triglyceride and HDL cholesterol were predictors of NASH in patients with genotype 1, whereas in patients with genotype 3, AST was the only predictor. 17659580 2007